Antibody–Drug Conjugates: Oncology and Beyond
- All day: November 14, 2017
- City/Town: New York, NY 10007-2157
- Location: New York
- Event Type: Conference & Exhibition Medical Scientific Symposium
- Website: Go to website
- Phone: +1 212 298 8600
- Organized by: Biochemical Pharmacology Discussion Group and the New York Academy of Sciences
Published on 23rd May
Antibody–Drug Conjugates (ADCs) combine the selectivity of antibodies with the efficacy of small molecule drugs, allowing for more precise therapeutic approaches. This symposium will explore the opportunities and challenges of ADCs for cancer, and the need to resolve these open questions in order to fulfill the larger promise of this technology. We will also consider use of ADCs beyond cancer into other disease indications including autoimmune disease, difficult-to-treat bacterial infections, and atherosclerosis.
| Organizers | Speakers |
|---|---|
| Gene Dubowchik, Ph.D, Bristol-Myers Squibb |
Philip E. Brandish, Ph.D, Merck & Co. |
| Lynn M. Abell, Ph.D, Bristol-Myers Squibb |
Ryan Fleming, Ph.D, MedImmune |
| Pamela A. Trail, Ph.D, Regeneron Pharmaceuticals Inc. |
Rakesh K. Jain, Ph.D, Harvard University |
| Sonya Dougal, Ph.D, The New York Academy of Sciences |
Christopher J. O’Donnell, Ph.D, Pfizer |
| Caitlin McOmish, Ph.D, The New York Academy of Sciences |
Laura Saunders, Ph.D, AbbVie |
| Greg Thurber, Ph.D University of Michigan |
Note: Poster Abstract Deadline is September 15, 2017
Print 
PDFShare
Featured Event
Topics to be Covered Introduction To Antibody Conjugates Overview Of Techniques In Quantitative Pharmacology No Such Thing As A Magic Bullet: The Hidden Challenges Of ADC Discovery And Development...